Filing Flows › Comparisons › VRDN vs VSTM
Viridian Therapeutics vs Verastem: VRDN and VSTM compared
Viridian Therapeutics is the larger company: $25.8M of revenue in its latest quarter (Q3 2026) against $24.0M for Verastem (Q3 2026). Verastem is growing faster (+114% against -64% a year earlier). Verastem is more profitable, with an operating margin of -313.3% against -401.8%.
Where the money goes: VRDN and VSTM
Viridian Therapeutics (VRDN) · Q3 2026
Viridian Therapeutics, Q3 2026: revenue $25.8M (-64% year over year), operating margin -401.8%, net loss $101M, operating cash flow −$92.8M. The chart follows the revenue to costs, profit and cash.
Verastem (VSTM) · Q3 2026
Verastem, Q3 2026: revenue $24.0M (+114% year over year), operating margin -313.3%, net loss $74.7M, operating cash flow −$33.6M. The chart follows the revenue to costs, profit and cash.
| Viridian Therapeutics (VRDN) | Verastem (VSTM) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $25.8M | $24.0M |
| Revenue growth, Y/Y | -64% | +114% |
| Operating margin | -401.8% | -313.3% |
| Net earnings | −$101M | −$74.7M |
| Net margin | -393.0% | -311.2% |
| Operating cash flow | −$92.8M | −$33.6M |
| Market value | — | $839M |
| Analysts’ mean target | — | $17.22 |
Where the revenue comes from
Viridian Therapeutics
- Product revenue, net: $24.7M (96%)
- Collaboration revenue: $956K (4%)
- License revenue: $125K (0%)
Questions
Which is bigger, Viridian Therapeutics or Verastem?
Viridian Therapeutics is the larger company: $25.8M of revenue in its latest quarter (Q3 2026) against $24.0M for Verastem (Q3 2026).
Is Viridian Therapeutics or Verastem growing faster?
Verastem is growing faster (+114% against -64% a year earlier).
Which is more profitable, Viridian Therapeutics or Verastem?
Verastem is more profitable, with an operating margin of -313.3% against -401.8%.
More: Viridian Therapeutics earnings · how Viridian Therapeutics makes money · Verastem earnings · how Verastem makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.